Jump to content

Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations (Q40384212)

From Wikidata

scientific article published on August 2005

Language	Label	Description	Also known as
default for all languages	No label defined
English	Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations	scientific article published on August 2005

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1 reference

based on heuristic

inferred from title

Lewis C. Cantley

10

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

object named as

Daniel G Tenen

11

0 references

13

object named as

Pasi A Jänne

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

author name string

Toru Mukohara

1

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Jeffrey A Engelman

2

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Nasser H Hanna

3

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Beow Y Yeap

4

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Susumu Kobayashi

5

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Neal Lindeman

6

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Balázs Halmos

7

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Joseph Pearlberg

8

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Zenta Tsuchihashi

9

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Bruce E Johnson

12

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

publication date

1 August 2005

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

language of work or name

0 references

Journal of the National Cancer Institute

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

97

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1185-1194

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

The EGF receptor family as targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

21 January 2018

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

21 January 2018

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

21 January 2018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

21 January 2018

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

21 January 2018

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

21 January 2018

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

21 January 2018

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

21 January 2018

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

21 January 2018

High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

21 January 2018

Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

21 January 2018

Sensitivity of non-small-cell lung cancer cell lines established from patients treated with prolonged infusions of Paclitaxel

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

21 January 2018

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

21 January 2018

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

21 January 2018

Establishment of a human non-small cell lung cancer cell line resistant to gefitinib.

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

21 January 2018

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

21 January 2018

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

21 January 2018

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

21 January 2018

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

21 January 2018

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

21 January 2018

Somatic mutations of epidermal growth factor receptor in colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

21 January 2018

Somatic mutations of EGFR in colorectal cancers and glioblastomas

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

21 January 2018

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

21 January 2018

A Farnesyl-Protein Transferase Inhibitor Induces p21 Expression and G1 Block in p53 Wild Type Tumor Cells

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

21 January 2018

Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

21 January 2018

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

21 January 2018

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

21 January 2018

Identifiers

10.1093/JNCI/DJI238

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40384212&oldid=1896716089"